Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.64 |
| ▸ | GSK3B | P49841 | 13/20 | 0.52 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.42 |
| ▸ | SRPK1 | Q96SB4 | 2/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | NEK4 | P51957 | 1/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 4/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22798252 | 0.87 | SCN9A (0.68) | SCN9AGSK3BMAPTGPR52MRGPRX4 | |
| SCHEMBL30450902 | 0.87 | SCN9A (0.68) | SCN9AGSK3BMAPTGPR52MRGPRX4 | |
| SCHEMBL22797762 | 0.86 | SCN9A (0.67) | SCN9AGSK3BMAPTGPR52MRGPRX4 | |
| SCHEMBL22797860 | 0.86 | GSK3B (0.52) | SCN9AGSK3BMAPTKDRGSK3A | |
| SCHEMBL20595154 | 0.86 | SCN9A (0.76) | SCN9AGSK3BMAPTMRGPRX4 | |
| SCHEMBL20595189 | 0.86 | SCN9A (0.66) | SCN9AGSK3BMAPTGPR52MRGPRX4 | |
| SCHEMBL30450528 | 0.86 | SCN9A (0.66) | SCN9AGSK3BMAPTGPR52MRGPRX4 | |
| SCHEMBL22809577 | 0.83 | SCN9A (0.63) | SCN9AGSK3BMAPTGPR52 | |
| SCHEMBL22798313 | 0.81 | SCN9A (0.59) | SCN9AGSK3BMAPTKDRGSK3A | |
| SCHEMBL22798321 | 0.79 | SCN9A (0.48) | SCN9AGSK3BMAPTGPR52CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | claimed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | claimed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | claimed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | claimed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | claimed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | claimed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | SCN9A 9/4885GSK3B 1727/4885MAPT 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.